Sarepta Therapeutics, Inc. Forecasted to Earn Q4 2018 Earnings of ($0.39) Per Share (SRPT)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at William Blair issued their Q4 2018 EPS estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Friday. William Blair analyst T. Lugo forecasts that the biotechnology company will post earnings of ($0.39) per share for the quarter. William Blair currently has a “Outperform” rating on the stock.
Other equities research analysts have also recently issued research reports about the stock. Oppenheimer Holdings, Inc. set a $76.00 price objective on shares of Sarepta Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 8th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Credit Suisse Group set a $64.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, July 18th. Leerink Swann reaffirmed a “buy” rating and set a $60.00 target price (up from $52.00) on shares of Sarepta Therapeutics in a research note on Tuesday, July 18th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $50.00 target price on shares of Sarepta Therapeutics in a research note on Thursday, July 20th. Nine research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $62.71.
Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at 45.36 on Monday. The company’s market capitalization is $2.92 billion. The stock’s 50 day moving average is $40.10 and its 200-day moving average is $34.92. Sarepta Therapeutics has a 12-month low of $26.26 and a 12-month high of $63.03.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter last year, the business posted ($1.19) EPS. The business’s quarterly revenue was up 350000.0% compared to the same quarter last year.
In other Sarepta Therapeutics news, SVP Alexander Cumbo sold 5,918 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $242,638.00. Following the sale, the senior vice president now owns 22,793 shares in the company, valued at $934,513. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Douglas S. Ingram bought 47,058 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 27th. The stock was acquired at an average price of $42.50 per share, for a total transaction of $1,999,965.00. Following the purchase, the chief executive officer now owns 382,058 shares of the company’s stock, valued at $16,237,465. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 78,056 shares of company stock valued at $3,224,208. 9.60% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. Prentiss Smith & Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 3,166 shares during the last quarter. Ameritas Investment Partners Inc. bought a new stake in Sarepta Therapeutics during the 1st quarter valued at about $127,000. PNC Financial Services Group Inc. lifted its holdings in Sarepta Therapeutics by 150.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Sarepta Therapeutics by 116.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares in the last quarter. Finally, Edge Wealth Management LLC bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at about $175,000. 65.41% of the stock is owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.